Hepatitis Awareness Month: Exploring the Latest Breakthroughs in Hepatitis


Hepatitis awareness remains essential to promote prevention and early detection, ensuring access to vaccination and treatment, and improving public health.

The CDC stresses the importance of hepatitis B virus (HBV) vaccination, but challenges in treatment accessibility persist.

Study Demonstrates Improvement in Monitoring for Hepatitis C Treatment in Prisons

Combating hepatitis C (HCV) transmission through integrated testing and enhanced use of direct-acting antivirals within the prison system can reduce incidence rates.

Investigational Hepatitis B Therapy is Granted FDA Fast-Track Status

GSK’s bepirovirsen received this designation, and the company has its sights on the therapy potentially providing a functional cure for the millions of people around the world who are affected by this form of viral hepatitis.

New Insights Into Hepatitis E Virus (HEV) Resistance

Study reveals HEV adaptation during treatment.

Global Access to Hepatitis C Treatments

Accessibility to direct-acting antivirals affecting low and middle-income countries.

Shortage in hepatitis b virus (HBV) clinical trials within the WHO African region.

Study exposes the adherence gap in HCV direct-acting antiviral therapy among people who inject drugs.

Study presented at CROI 2024 reveals chronic hepatitis B virus (HBV) infection heightens COVID-19 severity as vaccination reduces mortality and ICU demands in co-infected individuals.

Beneficial Treatment for Early-Stage Hepatitis C and HIV Co-Infection

Study shows the high efficacy of a 4-week glecaprevir/pibrentasvir regimen for a shorter, more manageable treatment duration.

The Role of Bulevirtide in Chronic Hepatitis D with HIV and HBV

Insights from phase 3 study evaluating bulevirtide efficacy in coinfections.

Enhancing Hepatitis B Vaccine Efficacy in People with HIV

Insights from CROI on the HepB-CpG vaccine trial.

Bulevirtide Demonstrates Efficacy, Safety for Hepatitis D Treatment

The first-in-class entry inhibitor delivered therapeutic benefits over a long study period for patients with chronic infection.

TherVacB's Journey Against Hepatitis B (HBV)

Vaccine designed to confront chronic HBV entering its first human clinical trial.

Enhancing Hepatitis B Screening Aiming Towards Elimination Goals

Wireless test kit transforms screening efforts towards combating the virus.

Preventing Mother-to-Child Transmission of Hepatitis C

Insights on Sofosbuvir levels in pregnant women.

Preventing the Entry of Hepatitis B and D Viruses

Bulevirtide's key role in blocking hepatitis virus entry.

Insights from a CDC study on challenges and research direction in pediatric hepatitis.

Guanylate Binding Protein 1 (GBP1) Supportive Role in Hepatitis C Virus (HCV) Assembly and Release

Study shows GBP1 assists HCV in the replication and spread against antiviral expectations.

HIV/Hepatitis B Virus (HBV) Coinfection Increases Risk of End-Stage Liver Disease

Study evaluates the outcomes of orthotopic liver transplantation of HIV-HBV coinfected patients.

Hepatitis B Virus (HBV) Bridges Gap Between Policy and Implementation in Vaccine Coverage

Danjuma Adda on WHO's efforts against Hepatitis B and his call for global vaccination and treatment efforts.

Current progress of WHO's strategies to enhance global health outcomes through improved diagnosis and treatment of viral hepatitis.

Chronic Hepatitis B Immunotherapeutic Vaccine Given Approval to Begin Trials

The vaccine’s developer, YS Biopharma, will begin its phase 1 clinical trial in the Philippines this summer.

Study from the Journal of Hepatology aims to characterize immune responses associated with rapid natural clearance of HCV reinfection.

Insights into Asymptomatic Hepatitis E virus Infections: Unveiling Dynamics and Kinetics

This study monitored viral load in asymptomatic blood donors, unveiling insights into the progression of HEV infections, vital for public health strategies.

Investigating Hepatitis B Virus-Related Hepatocellular Carcinoma Incidence

Study examines the scarcity of data on the incidence of HBV-related hepatocellular carcinoma in West Africa.

FDA Issues CRL for Dynavax's HEPLISAV-B Four-Dose Regimen in Hemodialysis Patients

Dynavax is currently reviewing FDA feedback and strategizing a meeting to discuss their HEPLISAV-B 4-dose regimen for hemodialysis patients, determining the path forward toward approval.

Research indicates serum LOXL2 levels could serve as a predictor for hepatocellular carcinoma (HCC) risk in HCV patients who have achieved sustained virological response (SVR).

Related Videos
© 2024 MJH Life Sciences

All rights reserved.